Tofacitinib (Xeljanz®) in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drug. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.
Rapid Review
| Commenced | Completed | Outcome |
| 08/03/2017 | 28/04/2017 | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations October 2017.
